Lenz Therapeutics has received approval from the Food and Drug Administration for Vizz (aceclidine ophthalmic solution) 1.44% ...

It is anticipated that Vizz, manufactured by Lenz Therapeutics, will become commercially available in the US by the end of ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

"This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and ...

LENZ Therapeutics continues to make strong progress in its U.S. commercial preparations for LNZ100, its investigational treatment for presbyopia, as the Company approaches the August 8, 2025 PDUFA ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...

LENZ Therapeutics’ product candidate addresses a widespread condition affecting approximately 1.8 billion people globally, highlighting the potential market size and opportunity for the company.

On Thursday, LENZ Therapeutics LENZ earned a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD ...

LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. have entered into an exclusive licensing and commercialization agreement for LNZ100, an aceclidine-based eye drop intended to treat ...